Hefei Xinzhu Biological Technology

Hefei Xinzhu Biological Technology is a clinical-stage biotechnology company based in Hefei, China, specializing in the development of innovative CAR-T cell therapies for autoimmune diseases. The company's lead program, XZ-011, is a CD19-targeted CAR-T therapy currently being evaluated in clinical trials for refractory myasthenia gravis and neuromyelitis optica spectrum disorder. By leveraging advanced cell engineering technologies, Hefei Xinzhu aims to provide long-term remission for patients with severe immune-mediated conditions. The company maintains strong ties with academic and clinical institutions in Anhui province to accelerate its translational research and clinical development efforts.